HeartSciences (NASDAQ:HSCS) Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS

HeartSciences (NASDAQ:HSCS) released its quarterly earnings results on Monday. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21, Zacks reports.

HeartSciences Trading Up 3.5%

NASDAQ:HSCS opened at $2.66 on Tuesday. The stock’s 50-day moving average is $3.01 and its 200-day moving average is $3.06. HeartSciences has a 1-year low of $2.01 and a 1-year high of $6.47. The stock has a market cap of $8.46 million, a P/E ratio of -0.39 and a beta of 2.53.

Institutional Investors Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Ascendiant Capital Markets raised their price target on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, HeartSciences has an average rating of “Hold” and a consensus target price of $9.20.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.